key: cord-0790756-a0gfn9tu
authors: Raveendran, A.V.; Misra, Anoop
title: Post COVID Syndrome (“Long COVID”) and Diabetes: Challenges in Diagnosis and Management
date: 2021-07-28
journal: Diabetes Metab Syndr
DOI: 10.1016/j.dsx.2021.102235
sha: 0ffb39bb64a92d43c6b7a793c1dddb88d5415000
doc_id: 790756
cord_uid: a0gfn9tu

Presence of various health issues even after recovering from acute COVID19 is collectively called post COVID syndrome (PCS, or “long COVID”). The symptoms of PCS can be due to organ dysfunction, effects of hospitalisation and drugs, or unrelated to these. Type 2 diabetes mellitus has bidirectional relationship with COVID-19. Presence of diabetes also influences PCS via various pathophysiological mechanisms. COVID-19 can add to or exacerbate postural hypotension with tachycardia, sarcopenia (and muscle fatigue), and microvascular dysfunction in patients with diabetes. Strict control of diabetes and other co-morbidities, supervised rehabilitation and physical exercise, and optimal nutrition could help in reducing and managing PCS. Patients may suffer from several debilitating symptoms/signs that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks after infection, and are not explained by an alternative diagnosis [1]. Common symptoms include fatigue, breathlessness, myalgia, weakness, headache, cognitive blunting etc. This conglomeration of symptoms is called “Long COVID” or more appropriately as “Post COVID-19 Syndrome (PCS)” [2]. The aim of the brief review is to summarise current knowledge of health events occurring after COVID-19 in brief and relate them for patients with diabetes.

Patients may suffer from several debilitating symptoms/signs that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks after infection, and are not explained by an alternative diagnosis [1] . Common symptoms include fatigue, breathlessness, myalgia, weakness, headache, cognitive blunting etc. This conglomeration of symptoms is called "Long COVID" or more appropriately as "Post COVID-19 Syndrome (PCS)" [2] . The aim of the brief review is to summarise current knowledge of health events occurring after COVID-19 in brief and relate them for patients with diabetes.

These symptoms often occur in cluster, often overlap with each other, and have tendency to wax and wane. The symptoms can be either persisting symptoms which occurred during acute COVID-19 infection, or new symptoms, and involve all organ systems [3] . In patients with health issues before SARS-CoV-2 infection, aggravation of pre-existing symptoms has also been noticed [4] . The most common symptoms is fatigue which is often profound and prolonged and shares characteristics with chronic fatigue syndrome (CFS) seen with other viral infections. Risk of PCS is more likely in those with more than 5 symptoms during acute COVID-19 and more in women, elderly, in obese individuals and in patients with diabetes [5, 6] . Further, persistent symptoms were more common in people with severe disease at presentation and in those with increased convalescent antibody titres [7] .

Based on the initial symptoms, duration of symptoms, period of quiescence and time of onset of symptoms long COVID (PCS) can be divided into five categories (Table 1 ) [8] . As can be noted from the classifications, symptoms could last 3-12 months, and vary in severity from mild to severe, or even lead to death. Based on pathophysiological mechanisms, we propose classification of PCS, which may help clinicians to plan its management in a rational manner (Table 2) .

Pathophysiologically, post COVID-19 syndrome is not a single clinical entity but a conglomeration of symptoms and signs due to multiple biological factors, which need more research. Commonly understood factors include organ damage, persistently dysregulated inflammatory and immune responses, and unrecognised microvascular thrombosis and endotheliitis [9] . Many other factors have been hypothesised; persistent tissue reservoirs of SARS-CoV-2, re-activation of other viruses, brainstem and/or vagus nerve dysfunctions and activation of autoimmunity due to molecular mimicry between pathogen and host proteins [10] . In addition, secondary infections (bacterial or fungal), effects of prolonged hospitalisation, sequelae of critical illness, post intensive care syndrome, drug side effects (e.g., corticosteroids), socioeconomic and psychological impact of the illness, may contribute [2, 11] . Further, protein and micronutrient deficiencies due to prolonged hospitalisation and poor oral intake, cause nutrient deficient state in patients with severe COVID-19 [12, 13] . This may be more common in Indian patients who have inadequate intake of protein and often Vitamin B12 and Vitamin D deficient [14] .

Type 2 diabetes mellitus (T2DM) has a bidirectional relationship with COVID-19 [15, 16] . Poorly controlled diabetes increases the severity of COVID-19 and is associated with increased morbidity and mortality. COVID-19 pandemic has also resulted in poor control of diabetes, progression of prediabetes to diabetes, increase in number of new onset diabetes and corticosteroid induced diabetes [15, 17] . Theoretically, it is possible that patients with long standing diabetes, which may by itself cause debilitation, could predispose to PCS. Long duration of uncontrolled diabetes cause organ damage, and in particular microvascular injury, and these can be exacerbated in patients with SARS-CoV-2 infection. Further, diabetes increases the risk of development of severe and critical illness, increases the risk of hospitalisation, and the need for mechanical ventilatory support, factors which can contribute to PCS. (Figure 1 ). One of the sequelae of lung involvement in patients with SARS-CoV-2 infection, i.e., pulmonary fibrosis, which can present with persistent breathlessness, requiring oxygen supplementation in post COVID-19 period, is more common in people with poorly controlled diabetes [18] . It is also reasonable to state that pre-existing low grade inflammatory state, as seen in T2DM, may get exacerbated and remains at a heightened state post COVID19 that may cause several symptoms. Post COVID-19, infections (e.g., Rhinocerebral Mucormycosis) may also contribute [19] . Corticosteroid therapy for COVID-19, widely practiced in India, poses further problems [20] . High dose corticosteroid therapy causes severe hyperglycaemia, electrolyte imbalance and myopathy.

Three issues need further deliberation since both diabetes and COVID19 may contribute in an overlapping manner. First is postural tachycardia syndrome (POTS), which is diagnosed based on the following criteria: orthostatic tachycardia (heart rate increase of > 30 beats per minutes in adults [> 40 beats per minute in patients aged 12-19 years] within 10 minutes of assuming upright posture) in the absence of orthostatic hypotension for at least 3 months [21] . Exact pathophysiology and long-term consequences of this syndrome are yet not known. Long standing diabetes may have autonomic neuropathy and dysfunction leading to tachycardia and postural hypotension, and these signs may get exacerbated in case POTS is co-existing. A combination of two will cause fatigue, tachycardia, and giddiness contributing to PCS.

Second issue is muscle weakness contributing to fatigue. In diabetes, neuropathy and myopathy contribute to muscle atrophy and sarcopenia [22] . COVID-19 infection, hospitalisation, protein deficiency and corticosteroid therapy often cause rapid onset sarcopenia in severe COVID-19 infections [23] . Further, many Indians, especially women, have low skeletal muscle mass and are sarcopenic [24] . Combined, skeletal muscles would become weaker than pre-COVID-19 period in patients with long duration of diabetes and particularly in elderly and women. This would cause fatigue, and limitation of walking, further adding to delay in rehabilitation.

A third situation is mostly hypothetical since not much of research is available. It is well known that diabetes can cause microvascular complications involving eyes, nerves and kidneys. What is not known is if these complications can be exacerbated by microvascular damage due to COVID-19. Interestingly, capillary dysfunction {capillary cell swelling and damage (endotheliitis), microthrombosis, pericyte damage, scarring etc.} has been hypothesised to cause multiple symptoms of PCS including fatigue, brain fog, and memory problems [9] . Theoretically, severe capillary damage can cause renal and other organ failures, a particularly worrying scenario in patients with diabetes [9] .

Rehabilitation of such patients is often slow and requires a multidisciplinary effort. For patients with diabetes, basic management principles must be adhered to. Strict glycaemic control and control of comorbidities during acute COVID-19 would reduce development of PCS and help manage it. Steroids should be used only when it is indicated, for the shortest duration with strict control of glycaemia. Prompt treatment of infection is important. Proper nutrition should be ensured, in particular, increase in protein intake and correction of vitamin and micronutrient deficiencies. Depending on symptoms, psychological counselling should be included in management. Physical therapy and exercise should be started after adequate period of rest but should not be delayed. Exercise may have multipronged beneficial effects; on sarcopenia, mental health, pulmonary efficiency, potentiation of immune J o u r n a l P r e -p r o o f system, and betterment of glycemia and blood pressure. It is preferable to be on individualised and supervised exercise training including aerobic and resistance exercises and muscles and chest physiotherapy [25] . On the positive side PCS improve with time in a significant portion of people. One study showed that the persistence of symptoms was seen in 13% lasting >28 days, 4.5% lasting >8 weeks and 2.3% >12 weeks [5] .

Overall, our understanding of PCS is improving but more research is needed. In particular, patients with diabetes would require care in glycemic and risk factor control to prevent the development and severity of PCS.

J o u r n a l P r e -p r o o f Symptoms with varying lengths of recovery and rehabilitation that directly correlate with the severity of infection, target organ damage and pre-existing medical conditions at the time of initial infection Type 2

Symptoms persisting 6 weeks from the time of initial infection Type 3

Period of quiescence or near-complete recovery following initial infection, followed by a return of symptoms that persist for ≥ 3 months (Type 3A) or ≥ 6 months (Type 3B) Type 4

Initially asymptomatic at the time of a positive SARS-CoV-2 test but develop symptoms beginning 1-3 months (Type 4A) or ≥ 3 months (Type 4B) later that persist for varying lengths of time Type 5

Initially asymptomatic or minimally symptomatic at the time of a positive SARS-CoV-2 test and experience sudden death within the next 12 months. *This category truly fits in the definition of post COVID syndrome or "long COVID" but some of these may also be partly due to other conditions listed above J o u r n a l P r e -p r o o f

COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (UK)

Long COVID: An overview

On Behalf Of The CAMFiC Long Covid-Study Group. Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management

Proposed integrative model for post-COVID symptoms

Attributes and predictors of long COVID

COVID-19 and Diabetes: A Collision and Collusion of Two Diseases

Long COVID in a prospective cohort of homeisolated patients

COVID-19 and its sequelae: a platform for optimal patient care, discovery and training

SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation

Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol

Infections and diabetes: Risks and mitigation with reference to India

Nutritional status of patients with COVID-19

National Diabetes Obesity and Cholesterol Foundation (NDOC), and Nutrition Expert Group, India. Balanced nutrition is needed in times of COVID19 epidemic in India: A call for action for all nutritionists and physicians

Balanced diet is a major casualty in COVID-19

Glycemic parameters in patients with new-onset diabetes during COVID-19 pandemic are more severe than in patients with new-onset diabetes before the pandemic: NOD COVID India Study

Diabetes and COVID19: a bidirectional relationship. Nutr Diabetes

Heterogeneity in presentation of hyperglycaemia during COVID-19 pandemic: A proposed classification

Uncontrolled Diabetes Mellitus: A Risk Factor for Post COVID Fibrosis

Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India

Steroid use during COVID-19 infection and hyperglycemia -What a physician should know

Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance

Type 2 Diabetes Mellitus is Associated with Increased Risk of Sarcopenia: A Systematic Review and Meta-analysis. Calcif Tissue Int

COVID-19 and Acute Sarcopenia

Dietary proteins, metabolic syndrome, and sarcopenia: Focus on Asian Indians

Post-COVID-19 Syndrome and the Potential Benefits of Exercise